Just 1 in 10 back pain treatments work, study says — what to do instead
Chronic back pain is the most common type of pain, affecting around 16 million American adults — and now a new study has revealed some discouraging findings about potential treatments.
Only around one in every 10 treatments was found to be effective in relieving lower back pain, according to a new study published in BMJ Evidence-Based Medicine.
Many of them are "barely better than a placebo" in terms of pain relief, as stated in a press release from the University of New South Wales (UNSW) in Sydney, Australia.
"Our review did not find reliable evidence of large effects for any of the included treatments," said lead study author Dr. Aidan Cashin, deputy director of the Centre for Pain IMPACT at Neuroscience Research Australia (NeuRA) and conjoint senior lecturer in the School of Health Sciences at UNSW Sydney.
The researchers reviewed 301 randomized, controlled trials that included data on 56 non-surgical treatments for adults experiencing acute low back pain, chronic low back pain or a combination of both types, comparing them to groups that received placebos.
"Treatments included in the research were pharmacological, such as non-steroidal anti-inflammatory drugs – or NSAIDs – and muscle relaxants, but also non-pharmacological, like exercise and massage," Cashin said.
Ineffective treatments for acute low back pain included exercise, steroid injections and paracetamol (acetaminophen), the study found.
For chronic low back pain, antibiotics and anaesthetics were also "unlikely to be suitable treatment options," the study found.
For acute low back pain, non-steroidal anti-inflammatory drugs (NSAIDs) could be effective, the study found.
For chronic low back pain, therapies including exercise, taping, spinal manipulation, antidepressants and transient receptor potential vanilloid 1 (TRPV1) agonists may be effective — "however, those effects were small," Cashin noted.
"Things like stress, sleep quality, fatigue, fear, social situations, nutrition, sickness and previous history of pain all play a role in how we experience pain."
The findings were "inconclusive" for many other treatments due to the "limited number of randomized participants and poor study quality," the researchers stated.
"We need further high-quality, placebo-controlled trials to understand the efficacy of treatments and remove the uncertainty for both patients and clinical teams," Cashin said.
Dr. Stephen Clark, a physical therapist and chief clinical officer at Confluent Health in Georgia, noted that the study was looking at "isolated interventions."
"They excluded studies where it was not possible to isolate the effectiveness of the target intervention," Clark, who was not involved in the study, told Fox News Digital.
Pain is a complex condition influenced by many different factors, according to Clark.
"Determining a specific cause of low back pain, particularly when the pain is persistent, is difficult, as the BMJ study points out," he said.
"Things like stress, sleep quality, fatigue, fear, social situations, nutrition, sickness and previous history of pain all play a role in how we experience pain."
Clark recommends "multimodal" treatments for pain, including multiple interventions tailored to each individual patient's experience.
"Physical therapy research shows that manual therapy (joint mobilization/manipulation, soft tissue techniques), active interventions like exercise, and education about why you hurt and what to do about it is the ticket," he said.
"It's also important to remember that what worked for someone else might not be the exact pathway that works for you."
While surgical intervention can be effective for some patients, Clark noted that it can present its own challenges and should be a "last resort" for non-emergency situations.
For more Health articles, visit www.foxnews.com/health
"While surgery is indicated in some cases, it's almost never the answer in isolation," he said. "Understanding pain and the complexity around a person's situation must be in view."
"In many cases, conservative care can prevent or delay the need for invasive procedures."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Atlantic
2 hours ago
- Atlantic
‘We're Just Becoming a Weapon of the State'
Since winning President Donald Trump's nomination to serve as the director of the National Institutes of Health, Jay Bhattacharya—a health economist and prominent COVID contrarian who advocated for reopening society in the early months of the pandemic—has pledged himself to a culture of dissent. 'Dissent is the very essence of science,' Bhattacharya said at his confirmation hearing in March. 'I'll foster a culture where NIH leadership will actively encourage different perspectives and create an environment where scientists, including early-career scientists and scientists that disagree with me, can express disagreement, respectfully.' Two months into his tenure at the agency, hundreds of NIH officials are taking Bhattacharya at his word. More than 300 officials, from across all of the NIH's 27 institutes and centers, have signed and sent a letter to Bhattacharya that condemns the changes that have thrown the agency into chaos in recent months—and calls on their director to reverse some of the most damaging shifts. Since January, the agency has been forced by Trump officials to fire thousands of its workers and rescind or withhold funding from thousands of research projects. Tomorrow, Bhattacharya is set to appear before a Senate appropriations subcommittee to discuss a proposed $18 billion slash to the NIH budget—about 40 percent of the agency's current allocation. The letter, titled the Bethesda Declaration (a reference to the NIH's location in Bethesda, Maryland), is modeled after the Great Barrington Declaration, an open letter published by Bhattacharya and two of his colleagues in October 2020 that criticized 'the prevailing COVID-19 policies' and argued that it was safe—even beneficial—for most people to resume life as normal. The approach that the Great Barrington Declaration laid out was, at the time, widely denounced by public-health experts, including the World Health Organization and then–NIH director Francis Collins, as dangerous and scientifically unsound. The allusion in the NIH letter, officials told me, isn't meant glibly: 'We hoped he might see himself in us as we were putting those concerns forward,' Jenna Norton, a program director at the National Institute of Diabetes and Digestive and Kidney Diseases, and one of the letter's organizers, told me. None of the NIH officials I spoke with for this story could recall another time in their agency's history when staff have spoken out so publicly against a director. But none of them could recall, either, ever seeing the NIH so aggressively jolted away from its core mission. 'It was time enough for us to speak out,' Sarah Kobrin, a branch chief at the National Cancer Institute, who has signed her name to the letter, told me. To preserve American research, government scientists—typically focused on scrutinizing and funding the projects most likely to advance the public's health—are now instead trying to persuade their agency's director to help them win a political fight with the White House. Bhattacharya, the NIH, and the Department of Health and Human Services did not respond immediately to a request for comment. The agency spends most of its nearly $48 billion budget powering science: It is the world's single-largest public funder of biomedical research. But since January, the NIH has canceled thousands of grants —originally awarded on the basis of merit—for political reasons: supporting DEI programming, having ties to universities that the administration has accused of anti-Semitism, sending resources to research initiatives in other countries, advancing scientific fields that Trump officials have deemed wasteful. Prior to 2025, grant cancellations were virtually unheard-of. But one official at the agency, who asked to remain anonymous out of fear of professional repercussions, told me that staff there now spend nearly as much time terminating grants as awarding them. And the few prominent projects that the agency has since been directed to fund appear either to be geared toward confirming the administration's biases on specific health conditions, or to benefit NIH leaders. 'We're just becoming a weapon of the state,' another official, who signed their name anonymously to the letter, told me. 'They're using grants as a lever to punish institutions and academia, and to censor and stifle science.' NIH officials have tried to voice their concerns in other ways. At internal meetings, leaders of the agency's institutes and centers have questioned major grant-making policy shifts. Some prominent officials have resigned. Current and former NIH staffers have been holding weekly vigils in Bethesda, commemorating, in the words of the organizers, ' the lives and knowledge lost through NIH cuts.' (Attendees are encouraged to wear black.) But these efforts have done little to slow the torrent of changes at the agency. Ian Morgan, a postdoctoral fellow at the NIH and one of the letter's signers, told me that the NIH fellows union, which he is part of, has sent Bhattacharya repeated requests to engage in discussion since his first week at the NIH. 'All of those have been ignored,' Morgan said. By formalizing their objections and signing their names to them, officials told me, they hope that Bhattacharya will finally feel compelled to respond. (To add to the public pressure, Jeremy Berg, who led the NIH's National Institute of General Medical Sciences until 2011, is also organizing a public letter of support for the Bethesda Declaration, in partnership with Stand Up for Science, which has organized rallies in support of research.) Scientists elsewhere at HHS, which oversees the NIH, have become unusually public in defying political leadership, too. Last month, after Health Secretary Robert F. Kennedy Jr.—in a bizarre departure from precedent—announced on social media that he was sidestepping his own agency, the CDC, and purging COVID shots from the childhood-immunization schedule, CDC officials chose to retain the vaccines in their recommendations, under the condition of shared decision making with a health-care provider. Many signers of the Bethesda letter are hopeful that Bhattacharya, 'as a scientist, has some of the same values as us,' Benjamin Feldman, a staff scientist at the National Institute of Child Health and Human Development, told me. Perhaps, with his academic credentials and commitment to evidence, he'll be willing to aid in the pushback against the administration's overall attacks on science, and defend the agency's ability to power research. But other officials I spoke with weren't so optimistic. Many at the NIH now feel they work in a 'culture of fear,' Norton said. Since January, NIH officials have told me that they have been screamed at and bullied by HHS personnel pushing for policy changes; some of the NIH leaders who have been most outspoken against leadership have also been forcibly reassigned to irrelevant positions. At one point, Norton said, after she fought for a program focused on researcher diversity, some members of NIH leadership came to her office and cautioned her that they didn't want to see her on the next list of mass firings. (In conversations with me, all of the named officials I spoke with emphasized that they were speaking in their personal capacity, and not for the NIH.) Bhattacharya, who took over only two months ago, hasn't been the Trump appointee driving most of the decisions affecting the NIH—and therefore might not have the power to reverse or overrule them. HHS officials have pressured agency leadership to defy court orders, as I've reported; mass cullings of grants have been overseen by DOGE. And as much as Bhattacharya might welcome dissent, he so far seems unmoved by it. In early May, Berg emailed Bhattacharya to express alarm over the NIH's severe slowdown in grant making, and to remind him of his responsibilities as director to responsibly shepherd the funds Congress had appropriated to the agency. The next morning, according to the exchange shared with me by Berg, Bhattacharya replied saying that, 'contrary to the assertion you make in the letter,' his job was to ensure that the NIH's money would be spent on projects that advance American health, rather than 'on ideological boondoggles and on dangerous research.' And at a recent NIH town hall, Bhattacharya dismissed one staffer's concerns that the Trump administration was purging the identifying variable of gender from scientific research. (Years of evidence back its use.) He echoed, instead, the Trump talking point that 'sex is a very cleanly defined variable,' and argued that gender shouldn't be included as 'a routine question in order to make an ideological point.' The officials I spoke with had few clear plans for what to do if their letter goes unheeded by leadership. Inside the agency, most see few levers left to pull. At the town hall, Bhattacharya also endorsed the highly contentious notion that human research started the pandemic—and noted that NIH-funded science, specifically, might have been to blame. When dozens of staffers stood and left the auditorium in protest, prompting applause that interrupted Bhattacharya, he simply smiled
Yahoo
2 hours ago
- Yahoo
My 5-year-old survived cancer – twice. Don't put politics before medical research.
Few issues in American politics have consistently united both parties like the fight against cancer. While funding levels and strategies may differ, Democrats and Republicans alike recognize that cancer doesn't discriminate – and neither should our commitment to defeat it. Under the Biden administration, the Cancer Moonshot was relaunched to accelerate progress toward a cure. More recently, President Donald Trump announced his 'Stargate' initiative, which aims to harness artificial intelligence in detecting and treating cancer, including through personalized mRNA vaccines. In the United States, cancer is the leading cause of death by disease for children after infancy. Across the political spectrum, there remains a shared hope: that no one should have to endure the pain of losing a loved one or fight this deadly disease. Yet today, that consensus is showing signs of strain. State legislatures across the country are advancing bills to ban or severely restrict the use of – and further research into – breakthrough technologies like mRNA, a technology that is driving promising advancements in cancer. What should be a story of American scientific innovation is being twisted into a political talking point. And it's putting lives at risk. Opinion: Biden's diagnosis shows two things. Cancer hits everyone and some forgot that. If the politicians pushing these bans spent even a few minutes inside a pediatric oncology unit, maybe they'd understand. They'd see floors filled with sick children on small bicycles, pulling IV poles behind them. Children in hospital beds, brave beyond measure. And parents clinging to hope. I've seen it firsthand. I'm a mother whose 5-year-old daughter has survived cancer – twice. My daughter Charlie is one of a small percentage of pediatric cancer patients whose tumors don't show up on standard blood tests. Her cancer went undetected for more than a year. By the time doctors found it, it had already spread to her liver. She was just 3 years old and had Stage 4 cancer. Once Charlie's cancer was detected, we rushed into treatment: high-dose chemotherapy, stem cell transplants and multiple surgeries. After months of treatment, we got the news every parent prays for: Charlie was cancer-free. But just a few months later, scans revealed a relapse. Two small nodules were found on her lung. Her baby brother was only two months old when we learned her cancer had returned. Relapse treatment was grueling. Charlie lost weight and muscle mass. She needed a feeding tube to stay nourished, hydrated and medicated. But through it all, she never lost her smile. Her strength became ours. And while we juggled caring for a newborn and two other children, we held onto hope, because science gave us a reason to. Thanks to expert care at Seattle Children's and research-backed protocols, she's once again cancer-free. She started preschool this year. She's coloring, laughing and chasing her siblings again. Every option we had was made possible by decades of public investment in research. Families who came before us joined clinical trials. Lawmakers chose to fund pediatric science and cancer research. That is the same kind of work mRNA research builds on today. Opinion alerts: Get columns from your favorite columnists + expert analysis on top issues, delivered straight to your device through the USA TODAY app. Don't have the app? Download it for free from your app store. Researchers are developing an mRNA-based diagnostic test that could catch cancers like hers earlier, when they're more treatable. The test uses mRNA from her original tumor to detect any circulating cancer cells through a simple blood draw. Catching a relapse early could be lifesaving. We first learned about this test in 2023, and knowing it's almost within reach brings us, and families like ours, so much hope. Beyond mRNA-based diagnostic tests, mRNA has also shown early promise as a therapy for cancer patients, enabling personalized treatment that could more effectively target one's tumor. That kind of innovation is exactly what's under threat right now. The role of mRNA technology in oncology has been studied for decades, and yet some lawmakers want to roll this progress back, arguing it is untested and unsafe. This technology, along with many innovations that come from federally supported medical research, is a critical source of hope for families around the world. I'm a doctor. So is my mother. When she got cancer, I realized how little that mattered. | Opinion When you're watching your child battle cancer, every advancement matters. I know firsthand how critical it is to catch cancer early and have access to every possible treatment option. When politicians politicize science – when they ban or restrict it based on misinformation and politics – they aren't protecting families like mine. They're limiting our options. They're slowing down the breakthroughs that could save lives. We can't afford to let misinformation and polarized politics dictate the future of lifesaving research. Thanks to innovation in medical research, Charlie is thriving today, but far too many kids are still fighting. Let's ensure science continues to move forward for all of our children. Emily Stenson is a childhood cancer advocate and the mother of 5-year-old two-time cancer survivor Charlie Stenson. She lives in Seattle. You can read diverse opinions from our USA TODAY columnists and other writers on the Opinion front page, on X, formerly Twitter, @usatodayopinion and in our Opinion newsletter. This article originally appeared on USA TODAY: Cancer research saved my child's life. Fund mRNA innovation | Opinion
Yahoo
4 hours ago
- Yahoo
Newsflash: Rocket Lab Makes Spy Satellites Now
Rocket Lab will buy spy satellite payload manufacturer Geost for up to $325 million in cash and stock. Rocket Lab already makes satellite buses for spy agencies and the military. Geost will allow it to make complete spy satellites. The purchase could help Rocket Lab bid for contracts under President Trump's Golden Dome plan. 10 stocks we like better than Rocket Lab › Rocket Lab (NASDAQ: RKLB) stock has taken off like -- what else? -- a rocket. Over the past 52 weeks, shares of the maker of tiny satellites and the only slightly bigger rockets that launch them has soared 521%, gaining about 10% per week. At nearly $27 per share currently, Rocket Lab carries a market capitalization of more than $13.3 billion, and is valued at 31 times its annual sales. Whatever might Rocket Lab be able to do to justify such an optimistic valuation? That's the question I asked myself (and CEO Peter Beck) when I interviewed him about the company's plans to build a new Neutron rocket -- and about the company's plans beyond Neutron -- a couple years back. And I came away with the firm opinion that Rocket Lab's most likely course, to expand its revenue streams and help justify its steadily increasing market capitalization, would be to build (or buy) its own satellite constellation. Turns out, though, Rocket Lab has decided to take neither of these routes, or at least not for now. Instead, Rocket Lab's next act will be to begin making spy satellites, and become a prime contractor selling such satellites directly to American spy agencies and the military. Rocket Lab's path to this new business goes by way of Geost, LLC, a tiny privately owned manufacturer of electro-optical payloads for the spy satellite market. Last week, Rocket Lab announced it will pay $125 million cash, plus $150 million in Rocket lab stock, plus another $50 million cash "in potential additional cash earnout payments tied to revenue targets" to buy Geost from the private equity firm that currently owns it. The purchase is slated to take place sometime in the second half of 2025. Once it happens, Rocket Lab will be able to build its own spy satellite "payloads," to couple with the satellite "buses" that it already builds to carry other companies' payloads. "Geost delivers advanced EO/IR sensor systems for missile warning and tracking, tactical intelligence, surveillance, and reconnaissance, Earth observation, and space domain awareness," explains Rocket Lab, referring to electro-optical and infrared sensors (or in more common parlance, "cameras"). Rocket Lab notes that these are precisely the kinds of cameras that the U.S. Pentagon is currently deploying en masse as part of the Space Force's Proliferated Warfighter Space Architecture (PWSA) program, for which Rocket Lab won a $515 million contract in 2023. These same kinds of cameras would be needed in even greater numbers to construct President Donald Trump's Golden Dome. Geost has until now been building these sensor suites for sale to major defense contractors such as Northrop Grumman and L3Harris, both of which are also major players in PWSA, and both of which are hopefuls for the Golden Dome project. Now, Geost will bring these capabilities in-house and help Rocket Lab to build entire spy satellites directly, "cementing the Company's role as a disruptor in national security space," and allowing the company to provide even more "end-to-end space capabilities for the United States and its allies." Simply put, it gives Rocket Lab a huge leg up in competing for future awards under PWSA, under Golden Dome, and for other spy satellite work -- not just for the U.S., but internationally as well. And let's be honest here: Rocket Lab really needs a boost like this, if its enormous valuation is to be justified. Priced in excess of $12.3 billion, but with less than $500 million in annual revenue and no profit or free cash flow, and not expected to turn profitable for another couple of years at least, Rocket Lab stock sells for a sky-high valuation of 26 times sales. Even assuming analyst forecasts are correct, it will be 2030 before Rocket Lab's sales (projected to be $3.5 billion that year) reach a level that brings the stock down to an ordinary valuation for a space stock -- somewhere between 2 and 4 times sales. Granted, growth stocks like Rocket Lab often sport excessive valuations to present-day sales. But to justify its valuation, Rocket Lab needs a really big growth driver, capable of rapidly expanding its annual sales. Buying Geost, and putting itself in contention to win prime contracts under the $175 billion Golden Dome project, just might be a catalyst big enough to make that happen. Before you buy stock in Rocket Lab, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rocket Lab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Rich Smith has positions in Rocket Lab USA. The Motley Fool has positions in and recommends L3Harris Technologies and Rocket Lab USA. The Motley Fool has a disclosure policy. Newsflash: Rocket Lab Makes Spy Satellites Now was originally published by The Motley Fool Sign in to access your portfolio
